Julie McHugh - 16 Jun 2026 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Reporting relationship: Director
Issuer ticker: IRWD
Reported as of: 16 Jun 2026
Net transaction value: -$80,460
SEC form: 4
Accepted by SEC: 17 Jun 2026, 16:41:40 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Amir Vitale, Attorney-in-Fact

Key filing fact

Julie McHugh filed Form 4 for IRONWOOD PHARMACEUTICALS INC (IRWD) on 17 Jun 2026.

Key facts

This page summarizes Julie McHugh's Form 4 filing for IRONWOOD PHARMACEUTICALS INC (IRWD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 16:41.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: -$80,460.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001487179 Primary reporting owner

McHugh Julie

Relationship: Director
Address: C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON
Signature: /s/ Amir Vitale, Attorney-in-Fact
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRWD transaction

Class A Common Stock

Award

Transaction value
Shares: +63,481
Change %: +30%
Price: $0.000000^*
Shares after: 272,320
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

IRWD transaction

Class A Common Stock

Sale

Transaction value: $80,460
Shares: -21,571
Change %: -7.9%
Price: $3.73
Shares after: 250,749
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.

Footnote F2

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Footnote F3

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.